Skip to search formSkip to main contentSkip to account menu

Tesevatinib

Known as: 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-(((3aalpha,5beta,6aalpha)-octahydro-2-methylcyclopenta(c)pyrrol-5-yl)methoxy)- 
An orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Tesevatinib binds to and… 
National Institutes of Health

Related topics

Related topics

11 relations
EGFR protein, humanERBB2 protein, humanInhibition of Cell ProliferationPositive Regulation of Apoptosis

Narrower (3)

EXEL-7647KD019XL647

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Tesevatinib. Tyrosine kinase inhibitor, Non-small cell lung cancer therapy, Treatment of glioblastoma, Treatment of polycystic kidney disease
2016
2016
EXTH-15. TESEVATINIB MONOTHERAPY EFFICACY AGAINST GBM12 IS ROBUST IN VITRO BUT RELATIVELY MODEST IN THE INTRACRANIAL GBM12 MODEL, DESPITE EXCELLENT BRAIN PENETRATION
2015
2015
A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC).
608 Background: Patients with HER2+ breast cancer (BC) have a high incidence of brain metastases (mets). Tesevatinib (formerly… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)